A prospective cohort study assessing the immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus
Latest Information Update: 05 Aug 2022
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms COVAC-SLE
Most Recent Events
- 05 Aug 2022 New trial record
- 26 Jul 2022 Results published in the Clinical and Experimental Rheumatology